Univariate, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.

1<p>Continuous variable, mean (standard deviation) presented.</p>2<p><18.5 in women; <20 in men; or malnutrition established clinically.</p>3<p>≤30% in women; ≤36% in men; when missing, also used hemoglobin ≤10 in women and ≤12 in men.</p>4<p>Dyspnea; resting respiratory rate greater than 26/minute.</p>5<p>Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS, pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin).</p>6<p>Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).</p>7<p>This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7), psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).</p

Distribution of covariates at initiation of ITR.

1<p>Continuous variable, mean (standard deviation) presented.</p>2<p><18.5 in women; <20 in men; or malnutrition established clinically.</p>3<p>≤30% in women; ≤36% in men; when missing, also used hemoglobin ≤10 in women and ≤12 in men.</p>4<p>Dyspnea; resting respiratory rate greater than 26/minute.</p>5<p>Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS, pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin).</p>6<p>Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).</p>7<p>This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7), psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).</p

Multivariable, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.

<p>Multivariable, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.</p

Treatment outcomes of 669 patients enrolled in individualized treatment for MDR-TB in Peru between February 1999 and July 2002. (Adapted from Mitnick et al., 2008) [20].

<p>Treatment outcomes of 669 patients enrolled in individualized treatment for MDR-TB in Peru between February 1999 and July 2002. (Adapted from Mitnick et al., 2008) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058664#pone.0058664-Mitnick2" target="_blank">[20]</a>.</p